[Federal Register Volume 66, Number 135 (Friday, July 13, 2001)]
[Notices]
[Pages 36793-36794]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-17537]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


National Mammography Quality Assurance Advisory Committee; Notice 
of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: National Mammography Quality Assurance Advisory 
Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on August 22, 2001, from 9 
a.m. to 6 p.m.
    Location: Holiday Inn, Walker/Whetstone Rooms, Two Montgomery 
Village Ave., Gaithersburg, MD.
    Contact: Charles Finder, Center for Devices and Radiological Health 
(HFZ-240), Food and Drug Administration, 1350 Piccard Dr., Rockville, 
MD 20850, 301-594-3332, or FDA Advisory Committee Information Line, 1-
800-741-8138 (301-443-0572 in the Washington, DC area), code 12397. 
Please call the Information Line for up-to-date information on this 
meeting.
    Agenda: The committee will review facility inspection findings and 
current compliance followup actions, the Mammography Quality Standards 
Act (the MQSA) compliance guidance, facility satisfaction survey, 
mammography access issues and the future direction of the MQSA program. 
The committee will also receive updates on the status of accreditation 
and certification of full field digital mammography, States as 
certification agencies under the MQSA, and the inspection demonstration 
project. The MQSA compliance guidance documents, which are in a 
question and answer format, are available to the public on the Internet 
at http://www.fda.gov/cdrh/mammography. This guidance is being updated 
continually in response to questions that FDA receives from the public. 
Additional information regarding guidance updates may be obtained by 
calling the Information Line.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by July 27, 2001. 
Oral presentations from the public will be scheduled between 
approximately 9:30 a.m. and 10:30 a.m. on August 22, 2001. Time 
allotted for each presentation may be limited. Those desiring to make 
formal oral presentations should notify the contact person before July 
27, 2001, and submit a brief statement of the general nature of the 
evidence or arguments they wish to present, the names and addresses of 
proposed participants, and an indication of the

[[Page 36794]]

approximate time requested to make their presentation.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: July 6, 2001.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 01-17537 Filed 7-12-01; 8:45 am]
BILLING CODE 4160-01-S